vs
Alkermes plc.（ALKS）与ARROWHEAD PHARMACEUTICALS, INC.（ARWR）财务数据对比。点击上方公司名可切换其他公司
Alkermes plc.的季度营收约是ARROWHEAD PHARMACEUTICALS, INC.的1.5倍（$384.5M vs $264.0M），Alkermes plc.净利率更高（12.8% vs 11.7%，领先1.2%），ARROWHEAD PHARMACEUTICALS, INC.同比增速更快（10461.3% vs -10.6%），Alkermes plc.自由现金流更多（$170.0M vs $11.3M）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
Arrowhead Pharmaceuticals是总部位于美国加利福尼亚州帕萨迪纳的上市生物制药企业，专注于通过RNA干扰（RNAi）作用机制开发创新药物，核心研发管线覆盖乙型肝炎、α-1抗胰蛋白酶缺陷相关肝病及心血管疾病的治疗领域。
ALKS vs ARWR — 直观对比
营收规模更大
ALKS
是对方的1.5倍
$264.0M
营收增速更快
ARWR
高出10471.9%
-10.6%
净利率更高
ALKS
高出1.2%
11.7%
自由现金流更多
ALKS
多$158.7M
$11.3M
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $264.0M |
| 净利润 | $49.3M | $30.8M |
| 毛利率 | 88.0% | — |
| 营业利润率 | 15.1% | 15.5% |
| 净利率 | 12.8% | 11.7% |
| 营收同比 | -10.6% | 10461.3% |
| 净利润同比 | -66.3% | 117.8% |
| 每股收益（稀释后） | $0.29 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKSARWR
| Q4 25 | $384.5M | $264.0M | ||
| Q3 25 | $394.2M | — | ||
| Q2 25 | $390.7M | — | ||
| Q1 25 | $306.5M | — | ||
| Q4 24 | $430.0M | — | ||
| Q3 24 | $378.1M | — | ||
| Q2 24 | $399.1M | — | ||
| Q1 24 | $350.4M | — |
净利润ALKSARWR
| Q4 25 | $49.3M | $30.8M | ||
| Q3 25 | $82.8M | — | ||
| Q2 25 | $87.1M | — | ||
| Q1 25 | $22.5M | — | ||
| Q4 24 | $146.5M | — | ||
| Q3 24 | $92.4M | — | ||
| Q2 24 | $91.4M | — | ||
| Q1 24 | $36.8M | — |
毛利率ALKSARWR
| Q4 25 | 88.0% | — | ||
| Q3 25 | 86.9% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.9% | — | ||
| Q4 24 | 85.6% | — | ||
| Q3 24 | 83.3% | — | ||
| Q2 24 | 84.6% | — | ||
| Q1 24 | 83.3% | — |
营业利润率ALKSARWR
| Q4 25 | 15.1% | 15.5% | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 23.8% | — | ||
| Q1 25 | 4.5% | — | ||
| Q4 24 | 37.8% | — | ||
| Q3 24 | 27.7% | — | ||
| Q2 24 | 27.5% | — | ||
| Q1 24 | 12.4% | — |
净利率ALKSARWR
| Q4 25 | 12.8% | 11.7% | ||
| Q3 25 | 21.0% | — | ||
| Q2 25 | 22.3% | — | ||
| Q1 25 | 7.3% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | 22.9% | — | ||
| Q1 24 | 10.5% | — |
每股收益（稀释后）ALKSARWR
| Q4 25 | $0.29 | $0.22 | ||
| Q3 25 | $0.49 | — | ||
| Q2 25 | $0.52 | — | ||
| Q1 25 | $0.13 | — | ||
| Q4 24 | $0.88 | — | ||
| Q3 24 | $0.55 | — | ||
| Q2 24 | $0.53 | — | ||
| Q1 24 | $0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $715.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $568.4M |
| 总资产 | $2.5B | $1.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKSARWR
| Q4 25 | $388.6M | $715.0M | ||
| Q3 25 | $616.4M | — | ||
| Q2 25 | $521.2M | — | ||
| Q1 25 | $399.8M | — | ||
| Q4 24 | $291.1M | — | ||
| Q3 24 | $396.3M | — | ||
| Q2 24 | $535.1M | — | ||
| Q1 24 | $420.8M | — |
股东权益ALKSARWR
| Q4 25 | $1.8B | $568.4M | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.6B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
总资产ALKSARWR
| Q4 25 | $2.5B | $1.6B | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.1B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $13.5M |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $11.3M |
| 自由现金流率自由现金流/营收 | 44.2% | 4.3% |
| 资本支出强度资本支出/营收 | 0.0% | 0.8% |
| 现金转化率经营现金流/净利润 | 3.45× | 0.44× |
| 过去12个月自由现金流最近4个季度 | $480.3M | — |
8季度趋势，按日历期对齐
经营现金流ALKSARWR
| Q4 25 | $170.1M | $13.5M | ||
| Q3 25 | $101.7M | — | ||
| Q2 25 | $150.2M | — | ||
| Q1 25 | $98.8M | — | ||
| Q4 24 | $190.4M | — | ||
| Q3 24 | $81.6M | — | ||
| Q2 24 | $146.0M | — | ||
| Q1 24 | $21.1M | — |
自由现金流ALKSARWR
| Q4 25 | $170.0M | $11.3M | ||
| Q3 25 | $84.4M | — | ||
| Q2 25 | $137.2M | — | ||
| Q1 25 | $88.7M | — | ||
| Q4 24 | $180.6M | — | ||
| Q3 24 | $73.3M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $12.8M | — |
自由现金流率ALKSARWR
| Q4 25 | 44.2% | 4.3% | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 28.9% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 3.6% | — |
资本支出强度ALKSARWR
| Q4 25 | 0.0% | 0.8% | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 2.4% | — |
现金转化率ALKSARWR
| Q4 25 | 3.45× | 0.44× | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 1.72× | — | ||
| Q1 25 | 4.40× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 1.60× | — | ||
| Q1 24 | 0.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
ARWR
暂无分部数据
